# Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

> **NCT00068757** · PHASE1 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 23 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** lonafarnib
- **DRUG:** paclitaxel
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00068757
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2007-11
- **Final completion:** —
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2012-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00068757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00068757, "Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/Neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00068757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*